John H. Burbank III Portfolio
Invests via Passport Capital LLC | Managed by John H. Burbank III
Invests via Passport Capital LLC
Managed by John H. Burbank III
Automatically Tracked
Chicago-based asset manager and founder with multi-decade experience in public and private markets, concentrating on value-oriented and event-driven strategies and macro portfolio construction. John H. Burbank III built firms that combine concentrated equity positions with operational engagement and board-level oversight, and frequently allocates to special situations and distressed opportunities. Active in capital formation, he maintains a track record of cross-asset allocation and philanthropic board service.
Chicago-based asset manager and founder with multi-decade experience in public and private markets, concentrating on value-oriented and event-driven strategies and macro portfolio construction. John H. Burbank III built firms that combine concentrated equity positions with operational engagement and board-level oversight, and frequently allocates to special situations and distressed opportunities. Active in capital formation, he maintains a track record of cross-asset allocation and philanthropic board service.
Investment Philosophy & Strategy
Combines value-driven, event-oriented investing with disciplined macro portfolio construction, favoring concentrated, high‑conviction equity positions and special-situations exposure. Seeks mispriced assets across public and private markets where operational engagement or board-level oversight can unlock value. Allocates opportunistically to distressed and catalyst‑led opportunities, balancing long-term fundamental conviction with tactical hedges and cross‑asset diversification to manage downside and compound capital over multi-year horizons.
Combines value-driven, event-oriented investing with disciplined macro portfolio construction, favoring concentrated, high‑conviction equity positions and special-situations exposure. Seeks mispriced assets across public and private markets where operational engagement or board-level oversight can unlock value. Allocates opportunistically to distressed and catalyst‑led opportunities, balancing long-term fundamental conviction with tactical hedges and cross‑asset diversification to manage downside and compound capital over multi-year horizons.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
-4.42%
Gain
Monthly
2.73%
Yearly
38.16%
Drawdown
53.95%
$17.27B
Equity
Holdings
$17.27B
Investment
$11.95B
$29.3B
Profit -$246.16M
Realized
$23.99B
Unrealized
$5.32B
Dividends
$50.37M
Goals
Avg. 100% completed goals
Yearly
Gain > 8% 2026
Yearly
Loss < $300M 2026
Yearly
Loss < 20% 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
0%
Profit
-$246.16M
Win %
74%
This Week
Compared To Last Week
Gain
-0.73%
Profit
-$127.31M
Win %
74%
This Month
Compared to last month
Gain
0.45%
Profit
$77.91M
Win %
74%
This Year
Compared to last year
Gain
15.27%
Profit
$2.29B
Win %
71%
SRZNW Surrozen Inc.
+23.44%
+$2,500 
SERA Sera Prognostics Inc.
+9.09%
+$989,670.6 
TSHA Taysha Gene Therapies Inc.
+4.04%
+$921,093.88 
CERS Cerus Corporation
+2.44%
+$750,625.87 
NRIX Nurix Therapeutics Inc.
+2.07%
+$2.22M 
ACAD Acadia Pharmaceuticals Inc.
+2%
+$21.88M 
PHVS Pharvaris N.V.
+1.34%
+$172,500 
IMVT Immunovant Inc.
+1.28%
+$2.7M 
SION Sionna Therapeutics Inc.
+1.08%
+$184,000 
MDGL Madrigal Pharmaceuticals, Inc.
+0.99%
+$11.35M 
IMTX Immatics N.V.
+0.98%
+$998,877.41 
SYRE Spyre Therapeutics, Inc.
+0.97%
+$965,000 
STOK Stoke Therapeutics Inc.
+0.89%
+$867,541.22 
VTVT vTv Therapeutics Inc.
+0.85%
+$40,044.78 
IMCR Immunocore Holdings plc American Depositary Receipt
+0.79%
+$194,615.2 
TCRX TScan Therapeutics Inc.
+0.75%
+$19,493.54 
KYMR Kymera Therapeutics Inc.
+0.71%
+$6.86M 
EVMN Evommune, Inc.
+0.42%
+$42,369.5 
IRON Disc Medicine Inc.
+0.4%
+$104,337.65 
TARA Protara Therapeutics Inc.
+0.37%
+$14,574.21 
VRDN Viridian Therapeutics Inc.
+0.34%
+$129,736.41 
ARGX argenx SE American Depositary Receipt
+0.32%
+$69,480.24 
GRAL Grail, Inc.
+0.3%
+$886,295.08 
CRNX Crinetics Pharmaceuticals Inc.
+0.23%
+$458,535.67 
DNLI Denali Therapeutics Inc.
+0.18%
+$149,267.8 
ELVN Enliven Therapeutics, Inc.
+0.14%
+$66,712.58 
RYTM Rhythm Pharmaceuticals Inc.
+0.07%
+$448,358.64 
XENE Xenon Pharmaceuticals Inc.
+0.04%
+$10,661.99 
ALKS Alkermes plc
+0.04%
+$200,245.34 
15102KAA8
0%
$0 
BEIGF BeiGene Ltd.
0%
$0 
CNTA Centessa Pharmaceuticals plc American Depositary Receipt
0%
$0 
CELC Celcuity Inc.
-20.16%
-$177.23M 
TECX Tectonic Therapeutic Inc.
-5.9%
-$1.25M 
KOD Kodiak Sciences Inc.
-5.56%
-$47.91M 
GENB Generate Biomedicines, Inc.
-5.2%
-$1.05M 
CMPS Compass Pathways plc Depositary Receipt
-5.15%
-$1.62M 
MPLT MapLight Therapeutics, Inc.
-5.05%
-$698,410.07 
GPCR Structure Therapeutics Inc.
-3.93%
-$2.85M 
CTNM Contineum Therapeutics, Inc.
-3.84%
-$795,669.28 
ABSI Absci Corporation
-3.62%
-$789,877.11 
ALGS Aligos Therapeutics Inc.
-3.52%
-$17,856.83 
RAPP Rapport Therapeutics Inc.
-3.19%
-$2.04M 
TYRA Tyra Biosciences, Inc.
-3.16%
-$11,031.28 
SKYE Skye Bioscience Inc.
-3.13%
-$30,559.71 
PRAX Praxis Precision Medicines Inc.
-2.92%
-$16.8M 
DBVT Dbv Technologies S.A. Sponsored ADR
-2.64%
-$613,798.5 
SMMT Summit Therapeutics Inc.
-2.4%
-$13.5M 
SANA Sana Biotechnology, Inc.
-2.38%
-$26,391.06 
WVE Wave Life Sciences Ltd.
-2.28%
-$115,169.32 
AKTS Akoustis Technologies Inc.
-2.22%
-$557,856.92 
ARWR Arrowhead Pharmaceuticals Inc.
-2.2%
-$3.15M 
VSTM Verastem Inc.
-1.98%
-$64,323.27 
RCUS Arcus Biosciences Inc.
-1.62%
-$191,185.66 
ALMS Alumis Inc.
-1.59%
-$875,437.5 
REPL Replimune Group Inc.
-1.42%
-$1.55M 
BCYC Bicycle Therapeutics plc American Depositary Receipt
-1.31%
-$598,694.64 
LBRX LB Pharmaceuticals Inc.
-1.28%
-$82,000 
DYN Dyne Therapeutics Inc.
-1.09%
-$211,496.74 
DNTH Dianthus Therapeutics Inc.
-1.03%
-$888,210.54 
DSGN Design Therapeutics, Inc.
-0.99%
-$349,882.82 
INSM Insmed Inc.
-0.93%
-$7.61M 
MIRM Mirum Pharmaceuticals Inc.
-0.93%
-$500,874.52 
IONS Ionis Pharmaceuticals, Inc.
-0.93%
-$1.04M 
XNCR Xencor Inc.
-0.82%
-$134,456.93 
GLUE Monte Rosa Therapeutics, Inc.
-0.72%
-$738,775.12 
SGMT Sagimet Biosciences Inc.
-0.7%
-$52,128.88 
CTMX CytomX Therapeutics Inc.
-0.55%
-$99,516.52 
ABCL AbCellera Biologics Inc.
-0.52%
-$1.06M 
RVMD Revolution Medicines Inc.
-0.51%
-$9.03M 
EIKN Eikon Therapeutics, Inc.
-0.47%
-$26,444.42 
PRLD Prelude Therapeutics Incorporated
-0.46%
-$202,476.48 
RLAY Relay Therapeutics Inc.
-0.33%
-$73,435.41 
ROIV Roivant Sciences Ltd
-0.23%
-$389,417.84 
KNSA Kiniksa Pharmaceuticals International, plc
-0.2%
-$354,976.5 
EWTX Edgewise Therapeutics, Inc.
-0.2%
-$526,075.2 
IDYA Ideaya Biosciences Inc.
-0.19%
-$276,256.05 
JBIO Jade Biosciences Inc.
-0.19%
-$65,645.48 
ABVX Abivax SA ADR
-0.17%
-$197,054.1 
BNTX BioNTech SE
-0.14%
-$15,303.16 
TRDA Entrada Therapeutics Inc.
-0.07%
-$25,363.65 
NGNE Neurogene Inc.
-0.07%
-$26,478.15 
CLDX Celldex Therapeutics Inc.
-0.07%
-$16,634.25 
INCY Incyte Corporation
-0.04%
-$1.54M Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 3650 | Longs Won 1882/3650 51% | Profit Factor 4.34 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $79.8M |
| Average Win $20.23M | Best Trade (Sep 30) $2.4B | Sharpe Ratio -23.75 |
| Average Loss -$4.96M | Worst Trade (Jul 09) -$807.89M | Z-Score -4.93 (100%) |
| Commissions $0 | Avg. Trade Length 2y 2m 1w 4d | Expectancy $8.03M |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.01% | 1.03% |
| Consecutive Losing Trades | 3,484 | 3,136 | 2,787 | 2,439 | 2,091 | 1,742 | 1,394 | 1,045 | 697 | 348 |
Hover over the desired column for a detailed explanation.
Returns
Overall, MonthlyNo Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
